SCHEMBL1930757

SCHEMBL1930757

Cc1ccccc1-c1nnc(-c2c(-c3ccccc3)noc2C)o1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.71
RAB9A P51151 6/20 0.63
NPC1 O15118 5/20 0.63
SMN1; SMN2 Q16637 5/20 0.63
TSHR P16473 4/20 0.63
ALDH1A1 P00352 4/20 0.63
HPGD P15428 3/20 0.63
CASP3 P42574 1/20 0.58
SENP8 Q96LD8 1/20 0.58
SENP7 Q9BQF6 1/20 0.58
SENP6 Q9GZR1 1/20 0.58
PTGS1 P23219 5/20 0.58
PTGS2 P35354 5/20 0.58
MAPT P10636 4/20 0.51
NPSR1 Q6W5P4 3/20 0.51
KMT2A Q03164 1/20 0.51
KDM4E B2RXH2 4/20 0.51
HSD17B10 Q99714 2/20 0.51
USP2 O75604 1/20 0.51
XBP1 P17861 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1930084 0.87 L3MBTL1 (0.67) L3MBTL1RAB9ANPC1SMN1; SMN2TSHR
SCHEMBL1929139 0.86 L3MBTL1 (0.68) L3MBTL1RAB9ANPC1SMN1; SMN2TSHR
SCHEMBL1930037 0.84 L3MBTL1 (0.65) L3MBTL1RAB9ANPC1SMN1; SMN2TSHR
SCHEMBL1931014 0.83 L3MBTL1 (0.67) L3MBTL1RAB9ANPC1SMN1; SMN2TSHR
SCHEMBL1929421 0.82 L3MBTL1 (0.63) L3MBTL1RAB9ANPC1SMN1; SMN2TSHR
SCHEMBL1929053 0.82 L3MBTL1 (0.65) L3MBTL1RAB9ANPC1SMN1; SMN2TSHR
SCHEMBL1929424 0.81 L3MBTL1 (0.61) L3MBTL1RAB9ANPC1SMN1; SMN2TSHR
SCHEMBL1928904 0.81 L3MBTL1 (0.61) L3MBTL1RAB9ANPC1TSHRALDH1A1
SCHEMBL1930755 0.81 NPC1 (0.61) L3MBTL1RAB9ANPC1SMN1; SMN2TSHR
SCHEMBL1930613 0.80 L3MBTL1 (0.60) L3MBTL1RAB9ANPC1SMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1968972-B1 ARYL-ISOXAZOLO-4-YL-OXADIAZOLE DERIVATIVES HOFFMANN LA ROCHE (CH) 2012-11-28 EP claimed
US-7541372-B2 Aryl-isoxazolo-4-yl-oxadiazole derivatives HOFFMAN-LA ROCHE INC. (US) 2009-06-02 US claimed
US-20070161686-A1 Aryl-isoxazolo-4-yl-oxadiazole derivatives HOFFMANN-LA ROCHE INC. 2007-07-12 US claimed
EP-1968972-B1 ARYL-ISOXAZOLO-4-YL-OXADIAZOLE DERIVATIVES HOFFMANN LA ROCHE (CH) 2012-11-28 EP disclosed
US-7956074-B2 Aryl-isoxazolo-4-yl-oxadiazole derivatives HOFFMAN-LA ROCHE INC. (US) 2011-06-07 US disclosed
US-20090197875-A1 ARYL-ISOXAZOLO-4-YL-OXADIAZOLE DERIVATIVES BUETTELMANN BERND 2009-08-06 US disclosed
US-7541372-B2 Aryl-isoxazolo-4-yl-oxadiazole derivatives HOFFMAN-LA ROCHE INC. (US) 2009-06-02 US disclosed
US-20070161686-A1 Aryl-isoxazolo-4-yl-oxadiazole derivatives HOFFMANN-LA ROCHE INC. 2007-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197875-A1 ARYL-ISOXAZOLO-4-YL-OXADIAZOLE DERIVATIVES GABRA5, GABRA4, GABRA3 L3MBTL1 3503/4885RAB9A 2522/4885NPC1 1684/4885
US-20070161686-A1 Aryl-isoxazolo-4-yl-oxadiazole derivatives GABRA5, GABRA4, GABRA3 L3MBTL1 3503/4885RAB9A 2522/4885NPC1 1684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.